340B Drug Pricing Program
Press Release
Hospital Data Show Skyrocketing Drug Prices
Contact:
Carly Sfregola, American Hospital Association (AHA), (202) 638-5487
Sean Brown, Federation of American Hospitals (FAH), (202) 624-1527
Tomorrow is the last day that hospitals can recertify for the 340B Drug Pricing Program. All 340B hospitals are required to recertify annually with the Health Resources and Services Administration to ensure they continue to meet 340B hospital eligibility requirements. To access a recent HRSA…
HRSA published in the Aug. 12 Federal Register a proposed rule implementing the Affordable Care Act provision requiring a binding administrative dispute resolution process for 340B Drug Pricing Program hospitals and clinics that claim they have been overcharged for drugs purchased through the…
The Health Resources and Services Administration today released a proposed rule that would implement an Affordable Care Act provision requiring a binding administrative dispute resolution process for 340B Drug Pricing Program participants who claim they have been overcharged for drugs…
The Health Resources and Services Administration's Office of Pharmacy Affairs will host a webinar July 20 to assist covered entities with the recertification process for the 340B Drug Pricing Program. Hospitals can join the webinar, from 1 p.m. to 2 p.m. ET, by visiting https://hrsa.…
Hospitals, including those participating in the 340B Drug Pricing Program, are the true safety-net, not the pharmaceutical industry with its “skyrocketing prescription drug prices and huge profits,” AHA Executive Vice President Tom Nickels writes in an AHASTAT blog post today.
A group financed by the pharmaceutical industry is hosting a meeting today on the 340B Drug Pricing Program with the goal of “Preserving the True Safety Net.” But what the meeting really will be about is the pharmaceutical industry – with their skyrocketing prescription drug prices and huge profits…
A recent proposal that calls for reducing the benefits of the 340B Drug Pricing Program to curb rapidly rising prescription drug costs is “misguided,” writes AHA Executive Vice President Tom Nickels in an AHASTAT blog post today.
The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.
Many groups, including the AHA, are evaluating options for addressing this important issue. However, one recent proposal, which is seriously misguided, would reduce a…